152 related articles for article (PubMed ID: 38601287)
21. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients.
Chen Y; Zhang T; Zhang R; Cao X
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38527247
[No Abstract] [Full Text] [Related]
22. Efficacy, toxicity and prognostic factors of pyrotinib‑involved neoadjuvant therapy in HER2‑positive breast cancer: A retrospective study.
Wang H; Cao H; Guo Z
Oncol Lett; 2023 Jul; 26(1):314. PubMed ID: 37332338
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín M; Chacón JI; Antón A; Plazaola A; García-Martínez E; Seguí MA; Sánchez-Rovira P; Palacios J; Calvo L; Esteban C; Espinosa E; Barnadas A; Batista N; Guerrero A; Muñoz M; Romio E; Rodríguez-Martín C; Caballero R; Casas MI; Rojo F; Carrasco E; Antolín S
Oncologist; 2017 Nov; 22(11):1301-1308. PubMed ID: 28701571
[TBL] [Abstract][Full Text] [Related]
24. A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.
Yang JX; Yang YQ; Hu WY; Yang L; Wu J; Wen XX; Yu J; Huang ML; Xu DD; Tie DC; Wang L; Li FF; Li NL
Oncologist; 2024 Jan; 29(1):e15-e24. PubMed ID: 37279780
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Futamura M; Ishihara K; Nagao Y; Ogiso A; Niwa Y; Nakada T; Kawaguchi Y; Ikawa A; Kumazawa I; Mori R; Kitazawa M; Hosono Y; Kuno M; Kawajiri M; Nakakami A; Takeuchi M; Morikawa A; Tokumaru Y; Katagiri Y; Asano Y; Mushika Y; Shimokawa T; Matsuhasih N
Breast Cancer; 2023 Mar; 30(2):293-301. PubMed ID: 36609911
[TBL] [Abstract][Full Text] [Related]
26. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.
Tian C; Wang M; Liu H; Liu J; Xu M; Ma L
Ir J Med Sci; 2023 Jun; 192(3):1041-1049. PubMed ID: 35829909
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Liang Y; Liu J; Ge J; Shi Q; Zhang G; Wan A; Luo T; Tian H; Fan L; Wang S; Chen L; Tang P; Zhu K; Jiang J; Bian X; Zhang Y; Qi X
EClinicalMedicine; 2024 May; 71():102585. PubMed ID: 38638401
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis.
Ma Q; Wei B; Wang BC; Wang G; Zhou X; Wang Y
Oncol Lett; 2024 May; 27(5):192. PubMed ID: 38495833
[TBL] [Abstract][Full Text] [Related]
30. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Zheng Y; Cao WM; Shao X; Shi Y; Cai L; Chen W; Liu J; Shen P; Chen Y; Wang X; Li H; Li M; Chen Z; Wang X
Nat Commun; 2023 Dec; 14(1):8314. PubMed ID: 38097605
[TBL] [Abstract][Full Text] [Related]
31. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.
Jin N; Xu Y; Wang S; Sun C; Yan X; Yang F; Liang Y; Chen W; Huang X
Cancer Pathog Ther; 2024 Jan; 2(1):31-37. PubMed ID: 38328709
[TBL] [Abstract][Full Text] [Related]
32. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
33. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
[TBL] [Abstract][Full Text] [Related]
34. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
35. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study.
Chai Y; Jiang M; Wang Y; Liu Q; Lu Q; Tao Z; Wu Q; Yin W; Lu J; Pu J
Front Cardiovasc Med; 2023; 10():1021937. PubMed ID: 36844736
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.
Wang W; Wang L; Chang JY; Hu F; Yan JY; Zhang J; Liang YP; Zhang HW; Wu HP; Cai HF
Gland Surg; 2022 Apr; 11(4):742-750. PubMed ID: 35531104
[TBL] [Abstract][Full Text] [Related]
37. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
Liu M; Zhou X
Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
[TBL] [Abstract][Full Text] [Related]
39. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
[TBL] [Abstract][Full Text] [Related]
40. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
